Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

  title={Factors underlying sensitivity of cancers to small-molecule kinase inhibitors},
  author={Pasi A. J{\"a}nne and Nathanael S. Gray and Jeffrey Settleman},
  journal={Nature Reviews Drug Discovery},
Selective small-molecule kinase inhibitors have emerged over the past decade as an important class of anti-cancer agents, and have demonstrated impressive clinical efficacy in several different diseases, including relatively common malignancies such as breast and lung cancer. However, clinical benefit is typically limited to a fraction of treated patients. Genomic features of individual tumours contribute significantly to such clinical responses, and these seem to vary tremendously across… 
Small molecule kinase inhibitors as anti-cancer therapeutics.
A broad overview of the relation between mechanism of action and the issues of target selectivity and resistance is provided and special attention was given to the kinase inhibitors currently in clinical trials.
Resistance to Targeted Therapies As a Result of Mutation(s) in the Target
This chapter addresses the different types of resistance mutations and the mechanisms by which they confer resistance to TKI, and the therapeutic strategies developed to overcome these resistance mutations.
Type II kinase inhibitors: an opportunity in cancer for rational design.
This work highlights the development made in Type II inhibitors, discussing the advantages and disadvantages of these types of molecules and presents the strategies for designing druggable molecules that either selectively inhibit target kinases or overcome drug resistance.
Functional analysis of mutant receptor tyrosine kinases involved in cancer pathogenesis
This study has successfully established cell models to study the biochemical properties and drug sensitivity of oncogenic mutations in EGFR, HER2 and FLT3 and uses these systems to test the effectiveness of small molecule inhibitors that target them.
Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
Interestingly, some of these TKIs also inhibit the ABC transporter mediated multi drug resistance (MDR) thereby; enhancing the efficacy of conventional chemotherapeutic drugs.
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
The Aurora kinase inhibitors in cancer research and therapy
  • J. Cicenas
  • Biology
    Journal of Cancer Research and Clinical Oncology
  • 2016
In this review, a number of AURK inhibitors and their use in cancer research and/or therapy are described to assist researchers and clinicians in deciding which inhibitor is most appropriate for their specific purpose.
Impact of genomic heterogeneity associated with acquired anti-EGFR resistance in colorectal cancers.
Cetuximab and panitumumab are anti-EGFR monoclonal antibodies approved by the Food and Drug Administration of the Unites States for treatment of patients with metastatic colorectal cancers, but the
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
The main molecular mechanisms of primary and acquired resistance to EGFR TKIs in EGFR-mutant NSCLC are addressed.


Targeting cancer with small molecule kinase inhibitors
This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors, and discusses the current challenges in the field.
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
Findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clinically responsive to pharmacologic ALK inhibition.
Showering c-MET-dependent cancers with drugs.
First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation: Positive Non-small Cell Lung Cancer Patients
  • L. Sequist
  • Biology, Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2008
The data describing the use of EGFR tyrosine kinase inhibitors in a genotype-directed population of NSCLC patients with EGFR mutations is summarized and areas that require further study are discussed.
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
  • G. Smolen, R. Sordella, D. Haber
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
It is shown that gastric cancer cells with high-level stable chromosomal amplification of the growth factor receptor MET are extraordinarily susceptible to the selective inhibitor PHA-665752, which may identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway.
Drug-sensitive FGFR2 mutations in endometrial carcinoma
It is shown that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma.
Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: Clues but no clear answers
The potential molecular mechanisms underlying mTOR activity, and how to improve the therapeutic value of mTOR inhibitors by combining them with other agents that may target different molecular pathways are discussed.
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro
These data provide scientific rationale for the clinical development of dasatinib in the treatment of women with “triple-negative” breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).
Antibody-Based Therapy for Solid Tumors
The mechanism behind each antibody, the registration trials for their approved indications, and emerging indications are the focus of this article.